RIFAMPICIN (R), 150mg, caps. blister
Valid Article
RIFAMPICIN (R)
- In the WHO list of Essential Medicines 2023 (Watch group antibiotics)
Therapeutic Action
Rifamycin bactericidal and antileprotic
Indications
Drug-Sensitive Tuberculosis (DS-TB)
Latent Tuberculosis Infection (LTI-TB)
Paucibacillary and multibacillary leprosy, in association with dapsone and clofazimine
Brucellosis, in combination with another antibacterial
Instructions for use
Tablet or capsule forms can be supplied according to availability when ordering.
When rifampicin is used in association with other TB medicines, fixes-dose combinations (FDC) are available:
- E 275mg / H 75mg / Z 400mg / R 150mg, tab., blister
- H 50mg / Z 150mg / R 75mg, disp. tab., blister
- E 275mg / H 75mg / R 150mg, tab., blister
- H 50mg / R 75mg, disp. tab., blister
- H 75mg / R 150mg, tab., blister
Blister packaging is the packaging of choice for antituberculosis medicines due to the unstable nature of some of them when exposed to higher temperatures and humidity.
Bulk packaging (hospital packs) should only be used in special circumstances or in case of unexpected problems in availability of the blister presentation.
The quantity to be ordered is calculated per tablet, not per blister.
Storage
Below 25°C ‐ Protect from sunlight ‐ Protect from humidity